Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.

We have recently shown that non-viral gene therapy can stabilise the decline of lung function in patients with cystic fibrosis (CF). However, the effect was modest, and more potent gene transfer agents are still required. Fuson protein (F)/Hemagglutinin/Neuraminidase protein (HN)-pseudotyped lentivi...

Полное описание

Библиографические подробности
Главные авторы:	Alton, E, Beekman, J, Boyd, A, Brand, J, Carlon, M, Connolly, M, Chan, M, Conlon, S, Davidson, H, Davies, J, Davies, L, Dekkers, J, Doherty, A, Gea-Sorli, S, Gill, D, Griesenbach, U, Hasegawa, M, Higgins, T, Hironaka, T, Hyndman, L, McLachlan, G, Inoue, M, Hyde, S, Innes, J, Maher, T, Moran, C, Meng, C, Paul-Smith, M, Pringle, I, Pytel, K, Rodriguez-Martinez, A, Schmidt, A, Stevenson, B, Sumner-Jones, S, Toshner, R, Tsugumine, S, Wasowicz, M, Zhu, J
Формат:	Journal article
Язык:	English
Опубликовано:	BMJ Publishing Group 2016

Схожие документы

Preparation for a first-in-man lentivirus trial in cystic fibrosis patients
по: Griesenbach, U, и др.
Опубликовано: (2016)

Moving lentiviral-based gene therapy into a first-in-man CF trial
по: Griesenbach, D, и др.
Опубликовано: (2015)

Towards a first-in-human trial with a pseudotyped lentivirus
по: Alton, EW, и др.
Опубликовано: (2020)

Production of SIV-F/HN: a new Lentivirus vector for CF gene therapy
по: Hyde, S, и др.
Опубликовано: (2015)

Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy.
по: Griesenbach, U, и др.
Опубликовано: (2012)

ASSESSMENT OF F/HN-PSEUDOTYPED LENTIVIRUS AS A CLINICALLY RELEVANT VECTOR FOR LUNG GENE THERAPY
по: Griesenbach, U, и др.
Опубликовано: (2012)

ASSESSMENT OF F/HN-PSEUDOTYPED LENTIVIRUS IN A CLINICALLY RELEVANT VECTOR FOR LUNG GENE THERAPY
по: Griesenbach, U, и др.
Опубликовано: (2012)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung.
по: Alton, E, и др.
Опубликовано: (2014)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung
по: Alton, E, и др.
Опубликовано: (2014)

Lentivirus gene therapy for autoimmune pulmonary alveolar proteinosis
по: Palau, H, и др.
Опубликовано: (2019)

The lung as a factory to produce secreted intrapulmonary and circulatory proteins
по: Paul-Smith, M, и др.
Опубликовано: (2017)

Cumulative CFTR expression following repeated aerosol delivery of non-viral pGM169/GL67A formulation to mouse lung
по: Alton, E, и др.
Опубликовано: (2012)

REPEAT ADMINISTRATION OF GL67A/PGM169 IS FEASIBLE, SAFE, AND PRODUCES ENDOGENOUS LEVELS OF CFTR EXPRESSION AFTER 12 DOSES
по: Alton, E, и др.
Опубликовано: (2012)

Lentivirus GM-CSF gene therapy for autoimmune pulmonary alveolar proteinosis
по: Lund-Palau, H, и др.
Опубликовано: (2018)

The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins
по: Paul-Smith, M, и др.
Опубликовано: (2018)

Lentivirus GM-CSF gene therapy ameliorates autoimmune pulmonary alveolar proteinosis
по: Lund-Palau, H, и др.
Опубликовано: (2018)

Recombinant Sendai virus vector to evaluate vector distribution in a large animal model of lung gene transfer
по: McLachlan, G, и др.
Опубликовано: (2004)

Pre-existing immunity to human parainfluenza virus (hPIV) does not affect rSIV.F/HN-mediated transduction efficiency
по: Pytel, K, и др.
Опубликовано: (2016)

Development of an immunocytochemical assay to detect human CFTR expression following gene therapy
по: Davidson, H, и др.
Опубликовано: (2008)

Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung.
по: McLachlan, G, и др.
Опубликовано: (2011)

TOXICOLOGY STUDIES IN SUPPORT OF THE UK CF GENE THERAPY CONSORTIUM'S MULTI-DOSE CLINICAL TRIAL
по: Griesenbach, U, и др.
Опубликовано: (2011)

Caprine lentivirus in sheep milk and semen
по: C.C.V. Lima, и др.

An immunocytochemical assay to detect human CFTR expression following gene transfer.
по: Davidson, H, и др.
Опубликовано: (2009)

Low levels of CFTR gene transfer with F/HN pseudotyped lentivirus are sufficient to generate ion transport correction in airway cell cultures from cystic fibrosis patients
по: Sergijenko, A, и др.
Опубликовано: (2020)

Genetic medicines for CF: Hype versus reality
по: Alton, E, и др.
Опубликовано: (2016)

A transitional endogenous lentivirus from the genome of a basal primate and implications for lentivirus evolution.
по: Gifford, R, и др.
Опубликовано: (2008)

OPTIMISATION OF MOLECULAR ASSAYS FOR CLINICAL TRIAL OF GL67A/PDNA DELIVERY TO NOSE AND LUNG OF CF PATIENTS
по: Sumner-Jones, S, и др.
Опубликовано: (2009)

Gene therapy for respiratory diseases; progress and a changing context
по: Alton, EWFW, и др.
Опубликовано: (2020)

DEVELOPMENT, PRODUCTION AND EVALUATION OF CLINICAL GRADE CFTR EXPRESSION PLASMID FOR CF LUNG GENE THERAPY
по: Gill, DR, и др.
Опубликовано: (2010)

The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep
по: Alton, E, и др.
Опубликовано: (2013)

The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep.
по: Alton, E, и др.
Опубликовано: (2013)

Discovery and analysis of the first endogenous lentivirus
по: Katzourakis, A, и др.
Опубликовано: (2007)

Discovery and analysis of the first endogenous lentivirus.
по: Katzourakis, A, и др.
Опубликовано: (2007)

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CYSTIC FIBROSIS: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY''
по: Davies, J, и др.
Опубликовано: (2009)

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CF: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY"
по: Davies, J, и др.
Опубликовано: (2009)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CYSTIC FIBROSIS
по: Davies, G, и др.
Опубликовано: (2011)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CF
по: Davies, J, и др.
Опубликовано: (2011)

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis
по: Alton, E, и др.
Опубликовано: (2013)

Update on the UK CF Gene Therapy Consortium Multidoes, non-viral, gene therapy trial
по: Alton, E, и др.
Опубликовано: (2012)

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis.
по: Alton, E, и др.
Опубликовано: (2013)